Selecting the right synthetic route early can determine whether a promising molecule advances efficiently or becomes delayed by low yield, unstable intermediates, difficult purification, costly raw materials, or scale-up failure. BOC Sciences provides Route Scouting and Development services for pharmaceutical, biotechnology, and specialty chemical projects that require practical, scalable, and cost-conscious synthetic strategies. Our process chemists evaluate multiple retrosynthetic options, screen feasible reactions, compare starting material availability, assess impurity risks, and develop robust pathways that can support discovery supply, lead optimization, pre-development material generation, and later-stage process refinement. By integrating synthetic chemistry, analytical insight, reaction engineering, and supply-chain awareness, we help clients transform challenging target structures into workable routes with clear experimental evidence and actionable development direction.
We design and compare multiple synthetic pathways by combining literature intelligence, reaction precedent, structure-based disconnection analysis, and practical manufacturing considerations. For broader chemistry programs, our route design can be integrated with Process R&D to create a clear development roadmap.
BOC Sciences moves beyond theoretical route planning by testing high-value route options at the bench. Promising transformations are experimentally assessed for conversion, selectivity, impurity formation, isolation behavior, and sensitivity to key reaction parameters.
After identifying a viable pathway, we improve the route through systematic reaction condition optimization, impurity control, work-up simplification, and yield enhancement to make the chemistry more reliable and transferable.
Our route development strategy is designed for chemistry that can move from milligram exploration to gram and kilogram preparation. When needed, the optimized route can be connected with scale-up support for larger material campaigns.
BOC Sciences helps pharmaceutical and biotechnology teams reduce route uncertainty, improve synthetic efficiency, and develop chemistry that supports reliable material generation.
Our chemists deconstruct target molecules into logical intermediates and commercially accessible fragments, then compare alternative disconnections based on feasibility, selectivity, route length, material cost, and downstream processing complexity.
Miniaturized and parallel experiments allow rapid comparison of reaction conditions, catalysts, bases, solvents, and additives, helping identify high-probability chemistry while minimizing consumption of valuable intermediates.
Route decisions are supported by structure characterization, reaction monitoring, impurity tracking, and intermediate confirmation to ensure that each selected pathway is backed by dependable chemical evidence.
We apply transition-metal catalysis, organocatalysis, and biocatalytic technology where appropriate to shorten routes, improve selectivity, and enable transformations that may be difficult using classical chemistry.
For transformations involving fast kinetics, hazardous intermediates, heat-sensitive steps, or mass-transfer limitations, our continuous flow reaction technology can be evaluated as a route-enabling option.
We identify likely impurity sources, side reactions, degradation pathways, and carryover risks so that route selection considers not only target formation but also practical purification and long-term process control.
BOC Sciences supports route scouting and development for a broad range of synthetic targets, from early discovery compounds to advanced intermediates and complex APIs. Each program is customized according to molecular complexity, available synthetic information, target quantity, timeline pressure, and desired development depth.
Send your target structure, current synthesis, key bottlenecks, and required material scale. BOC Sciences will evaluate feasible route options and recommend a practical development direction.
We review the target structure, existing synthetic records, literature precedents, available starting materials, stereochemical requirements, and known bottlenecks. The result is a route landscape that separates high-value options from routes that are likely to be impractical, expensive, or difficult to purify.
Selected routes are tested experimentally, with emphasis on the highest-risk bond-forming steps, intermediate stability, reaction selectivity, and work-up behavior. We use analytical monitoring to compare reaction outcomes and identify the most promising chemistry for further development.
The preferred pathway is refined through condition optimization, impurity control, telescoping assessment, isolation improvement, and solvent or reagent replacement where beneficial. For purification-sensitive molecules, our analysis and purification capabilities help resolve route-limiting separation challenges.
We deliver a clear route recommendation supported by experimental data, reaction conditions, analytical observations, impurity considerations, material balance, and practical next steps. When required, the route package can be connected to tech transfer services for smooth handoff to internal or external development teams.
Discovery chemistry often prioritizes speed over route efficiency, leaving clients with long sequences, difficult isolations, and poor overall yield. BOC Sciences redesigns these pathways by identifying earlier convergent steps, replacing unstable intermediates, improving chemoselectivity, and removing avoidable purification burdens so that the route becomes more suitable for reliable material preparation.
Molecules with one or more stereocenters may require asymmetric synthesis, resolution, chiral pool strategies, or late-stage stereochemical control. BOC Sciences evaluates multiple approaches and can integrate chiral analysis and separation to confirm enantiomeric composition and support selection of the most practical stereochemical route.
Route-limiting impurities can arise from side reactions, reagent carryover, unstable intermediates, or competing reaction pathways. Our team applies impurity pathway mapping, reaction monitoring, and impurity isolation and identification to understand impurity origin and redesign the route or conditions for cleaner conversion.
Some bench-scale routes fail when reaction heat, mixing, precipitation, gas evolution, or reagent addition becomes harder to control. BOC Sciences evaluates scale-sensitive operations early, replaces hazardous or impractical steps where possible, and develops route options that are better aligned with larger-batch execution and predictable product isolation.
Whether you need an alternative route, a cleaner synthesis, a scalable pathway, or a route comparison for a complex target, BOC Sciences provides the chemistry expertise and experimental depth to support confident decision-making.
We focus on synthetic pathways that can be experimentally tested, optimized, and executed. Our route recommendations consider actual reaction behavior, intermediate handling, isolation feasibility, and material availability rather than theoretical elegance alone.
Route decisions are supported by reaction monitoring, intermediate confirmation, impurity assessment, and analytical troubleshooting, helping clients avoid costly assumptions and select pathways based on reliable chemical evidence.
Our team supports early medicinal chemistry routes, gram-scale material generation, advanced intermediate development, and pre-scale process refinement. Service scope can range from route proposal only to full experimental route development.
BOC Sciences has experience with heterocycles, chiral molecules, fluorinated compounds, macrocycles, sensitive intermediates, and multi-step API synthesis, enabling tailored solutions for structures that do not fit routine synthetic pathways.
Client Needs: A biotechnology client needed gram quantities of a bicyclic heteroaryl API intermediate for repeated pharmacology studies. Their discovery route required nine steps, two chromatographic purifications, and a low-yielding late-stage amination.
Challenges: The original route used an expensive halogenated precursor and generated regioisomeric impurities that were difficult to purge. The final amination also showed inconsistent conversion when the batch size increased beyond small screening scale.
Solution: BOC Sciences redesigned the synthesis around an earlier convergent coupling and replaced the late-stage amination with a more selective C-N bond-forming sequence. We screened bases, ligands, and solvent systems, then introduced crystallization-based isolation to remove chromatographic dependence. The revised route shortened the sequence, improved intermediate stability, and generated a clearer impurity profile.
Outcome: The client received a practical route suitable for repeated gram-scale preparation, with fewer isolations, improved overall yield, and a more predictable process for future material campaigns.
Client Needs: A pharmaceutical research team required a scalable route to a chiral lactam-containing candidate with two adjacent stereocenters. The initial route relied on low-throughput chiral separation and produced inconsistent diastereomeric ratios.
Challenges: The molecule was sensitive to strong base, and late-stage epimerization occurred during work-up. The client needed a route that controlled stereochemistry earlier and reduced dependence on preparative separation.
Solution: We evaluated chiral pool, asymmetric reduction, and auxiliary-based strategies, then selected an asymmetric hydrogenation approach supported by rapid catalyst screening. Reaction conditions were refined to suppress epimerization, and NMR plus chiral HPLC confirmed stereochemical outcomes at each key stage. A mild crystallization process was introduced for diastereomer enrichment.
Outcome: BOC Sciences delivered a stereochemically controlled route with improved selectivity and simpler purification, allowing the client to generate material with greater confidence and reduced separation burden.
Client Needs: A small molecule development group approached BOC Sciences with an indazole-based kinase inhibitor route that repeatedly produced a persistent oxidative impurity during the final two synthetic steps.
Challenges: The impurity co-eluted with the target compound under several HPLC methods and increased during concentration. Without understanding its origin, the client could not decide whether to modify the route or only adjust purification.
Solution: BOC Sciences combined LC-MS tracking, forced reaction stress experiments, and intermediate resynthesis to locate the impurity source. We identified an air-sensitive intermediate and redesigned the final coupling under inert conditions with controlled addition. A revised solvent exchange and low-temperature isolation step prevented impurity growth during concentration.
Outcome: The revised route reduced the impurity to a manageable trace level, simplified purification, and gave the client a mechanistic understanding of the degradation pathway for future process control.
Route scouting is the systematic evaluation of possible synthetic pathways to identify the most practical, efficient, and scalable route for a target compound. Instead of focusing only on whether a molecule can be synthesized, route scouting compares starting material availability, step count, reaction selectivity, impurity risks, isolation complexity, cost drivers, and process robustness. For pharmaceutical development teams, it provides an informed foundation for selecting a synthesis strategy that can support reliable downstream development.
A synthetic route should be reconsidered when it depends on expensive or difficult-to-source starting materials, uses hazardous or harsh reaction conditions, gives inconsistent yields, produces difficult-to-remove impurities, requires repeated chromatography, or shows poor performance during scale-up attempts. Route redesign may also be valuable when the target structure changes, when a more convergent synthesis is possible, or when a client needs a route better aligned with long-term development and manufacturing objectives.
Route development reduces project risk by identifying weak points before they become costly technical barriers. Through reaction screening, intermediate stability assessment, impurity tracking, solvent and reagent evaluation, and early scalability studies, development scientists can determine which steps are robust and which require replacement or optimization. BOC Sciences supports this process by combining retrosynthetic analysis with experimental verification, helping clients avoid routes that appear feasible at small scale but are unreliable for continued development.
A scalable route typically uses accessible raw materials, avoids unnecessary protection and deprotection steps, delivers consistent conversion and selectivity, minimizes difficult purifications, and maintains predictable performance under larger reaction volumes. Practical scalability also depends on manageable heat transfer, mixing behavior, crystallization or isolation efficiency, and impurity control. A route that works well on milligram scale may still require substantial adjustment before it becomes suitable for gram- to kilogram-level preparation.
BOC Sciences provides customized route scouting and development support for small molecules, complex intermediates, and specialized building blocks. Our team can evaluate literature and patent routes, design alternative synthetic strategies, screen reaction conditions, optimize key transformations, investigate impurity formation, and assess practical scalability. For clients with an existing route, we can improve yield, simplify purification, replace problematic reagents, and develop a more robust process tailored to project-specific goals.
BOC Sciences helped us compare three possible synthetic pathways and quickly identify which one deserved experimental investment. Their recommendation was practical, data-driven, and immediately useful for our internal planning.
— Dr. Michael R., Director of Medicinal Chemistry
Our discovery route worked only on tiny batches. BOC Sciences redesigned the key steps, reduced purification complexity, and gave us a route that our team could reproduce with confidence.
— Laura S., Project Manager, Small Molecule Development
Their chemists quickly identified why our late-stage reaction was generating multiple impurities. The modified sequence they proposed made the chemistry cleaner and saved us from repeating unproductive optimization cycles.
— Dr. Elena K., Senior Research Scientist
We appreciated that BOC Sciences considered raw material availability, isolation, solvent use, and safety from the beginning. Their route scouting was not just creative chemistry; it was development-minded chemistry.
— James L., Head of CMC Strategy
If you have any questions or encounter issues on this page, please don't hesitate to reach out. Our support team is ready to assist you.
